EAM Investors LLC Invests $5.96 Million in Scholar Rock Holding Co. (NASDAQ:SRRK)

EAM Investors LLC purchased a new position in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 137,861 shares of the company's stock, valued at approximately $5,958,000. Scholar Rock comprises approximately 0.8% of EAM Investors LLC's investment portfolio, making the stock its 8th biggest holding. EAM Investors LLC owned approximately 0.15% of Scholar Rock as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in SRRK. Wellington Management Group LLP raised its stake in shares of Scholar Rock by 16.2% in the third quarter. Wellington Management Group LLP now owns 199,777 shares of the company's stock valued at $1,600,000 after buying an additional 27,801 shares during the period. Barclays PLC increased its stake in Scholar Rock by 103.4% in the 3rd quarter. Barclays PLC now owns 165,449 shares of the company's stock worth $1,324,000 after acquiring an additional 84,118 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Scholar Rock by 7.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company's stock valued at $759,000 after acquiring an additional 6,269 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Scholar Rock by 8.5% in the third quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock worth $12,361,000 after purchasing an additional 120,489 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Scholar Rock by 17.6% in the fourth quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after purchasing an additional 708,817 shares in the last quarter. 91.08% of the stock is owned by institutional investors.

Scholar Rock Stock Performance

Scholar Rock stock traded up $0.18 during mid-day trading on Monday, reaching $30.93. 256,762 shares of the stock traded hands, compared to its average volume of 1,233,361. The business's 50-day moving average is $33.26 and its 200-day moving average is $35.47. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The stock has a market capitalization of $2.93 billion, a PE ratio of -13.16 and a beta of 0.56.

Insiders Place Their Bets

In other Scholar Rock news, insider Tracey Sacco sold 6,500 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $33.08, for a total transaction of $215,020.00. Following the completion of the sale, the insider now owns 71,750 shares of the company's stock, valued at approximately $2,373,490. The trade was a 8.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jay T. Backstrom sold 18,372 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $676,640.76. Following the completion of the sale, the chief executive officer now directly owns 311,991 shares of the company's stock, valued at $11,490,628.53. This represents a 5.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 250,231 shares of company stock worth $9,056,086. Company insiders own 19.20% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wedbush reissued an "outperform" rating and issued a $50.00 price target on shares of Scholar Rock in a research note on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $42.67.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.